While there is no cure for multiple myeloma, increased awareness about the symptoms can be the key to timely diagnosis and ...

A new research paper was published in , Volume 16, on March 21, 2025, titled "NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma." ...

Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma. Advanced disease and extramedullary involvement are common clinical features at presentation.

A new research paper was published in Oncotarget, Volume 16, on March 21, 2025, titled “NSD2-epigenomic reprogramming and ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events ...

Our findings suggest a role for NSD2 in maintaining MM cell identity, with potential implications for future therapeutic strategies based on ...

The study in the European Respiratory Journal used advanced spatial mapping techniques to compare healthy lung tissues and ...

What Is Refractory Multiple Myeloma? Multiple myeloma is a cancer that affects a type of white blood cell called a plasma cell, which helps your immune system fight infections. Refractory means ...

NICE has made 97 positive recommendations for blood cancer treatments over the last decade, five times more than in the previous ten years. 92% of blood cancer treatment recommendations since 2015 ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...